Alzheimer’s and amyloid: ‘It’s time to do something else’
I f there is anything more certain than the failure of experimental Alzheimer’s drugs — nearly 300, at last count
Read More
Part D/Prescription Drugs
It Will Take More Than Transparency To Reduce Drug Prices, Economists Say
(By Alison Kodjak for NPR) A new drug to treat postpartum depression is likely to reach the U.S. market in
Read MoreBiogen halts studies of closely watched Alzheimer’s drug, a blow to hopes for new treatment
(By Adam Feuerstein for ST A T) A lzheimer’s disease has beaten back another effort to tame it. Biogen and
Read More“Affordability boards” to review expensive drugs
To rein in prescription drug prices, several states are considering new “affordability boards” to review expensive drugs and if it
Read MoreFentanyl-Linked Deaths: The U.S. Opioid Epidemic’s Third Wave
(By Martha Bebinger for NPR) Men are dying after opioid overdoses at nearly three times the rate of women in
Read MoreBiosimilar approval and adoption in the U.S. needs to be expedited
(By Carlos Sattler and Sheila Frame for ST A T) G eneric versions of brand-name small-molecule drugs saved Americans more
Read MoreWhen medicines are unaffordable, here’s how patients cut costs
(By Megan Thielking for ST A T) O ne in five U.S. adults prescribed medicines say they’ve asked their doctor
Read MoreHow the not-for-profit Civica Rx will disrupt the generic drug industry
(By Marc Harrison for ST A T) T he generic drug industry should cause prices for medications to drop. But
Read MoreTime is running out if you want to change your Medicare Advantage plan
Time is running out if you want to change your Medicare Advantage plan or switch back to original Medicare. You
Read MoreFDA approves new generic for valsartan
After multiple recalls of a certain generic valsartan medications, the U.S. Food and Drug Administration has approved a new generic
Read More